ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO750

Efficacy of Sacubitril/Valsartan in Patients With Cardiorenal Syndrome

Session Information

Category: Hypertension and CVD

  • 1502 Hypertension and CVD: Clinical‚ Outcomes‚ and Trials

Authors

  • Zhang, Yue, Sichuan Academy of Medical Sciences and Sichuan People's Hospital, Chengdu, Sichuan, China
  • Hong, Daqing, Sichuan Academy of Medical Sciences and Sichuan People's Hospital, Chengdu, Sichuan, China
  • Li, Guisen, Sichuan Academy of Medical Sciences and Sichuan People's Hospital, Chengdu, Sichuan, China
Background

To retrospectively study the efficacy of Sacubitril/Valsartan in patients with cardiorenal syndrome (CRS).

Methods

In-hospital patients with CRS who admitted in heart failure(HF) center of our hospital from October 2021 to December 2021, meeting inclusion criteria were involved: age>18y, diagnosed as cardiorenal syndrome and receiving maximum tolerated doses of sacubitril/valsartan therapy(400mg/d) for 3 months. Clinical data were collected at the baseline and 3-month endpoint to assess cardiac and renal function.

Results

69 patients with CRS were observed and participated. After 3-month’s therapy, mean sitting systolic pressure(msSBP), mean sitting diastolic pressure(msDBP) , heart-rate , type-B natriuretic peptide (BNP) and serum uric acid (sUA) were improved significantly, p-value was 0.000, 0.001,0.011,0.004,0.000 respectively. All the patients were divided into 2 subgroups based on the left ventricular ejection fraction(LVEF) value: group A( EF more than 50%) and group B (EF less than 50%). LVEF and left ventricular (LV) diameter were significantly improved in group B (p=0.008). Kidney function assessed by estimated glomerular filtration rate (eGFR) and serum creatinine (sCr) were improved but not significantly in all patients (p=0.696, 0.514 respectively) and group B (p=0.297, 0.534 respectively).

Conclusion

Sacubitril/valsartan might effectively decrease blood pressure and improve cardiac function in patients with CRS. And it seems like be effective to preserving kidney function ,especially in CRS patients with lower EF value. It need to be verified in large scale controlled prospective trials.